EMA (European Medicines Agency) has published this proposed plan for advancing the Agency’s engagement with regulatory science over the next five to ten years, covering both human and veterinary medicines.
The strategy includes developments and challenges in medicines development that EMA together with the Commission and NCAs experts have identified in a thorough process of
mapping and selection. Now EMA wants to hear from stakeholders.
See: https://www.ema.europa.eu/documents/regulatory-procedural-guideline/ema-regulatory-science-2025-strategic-reflection_en.pdfPosted by Dr. Tim Sandle, Pharmaceutical Microbiology
